• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Axonis Therapeutics Announces $115 Million Series A Financing

    10/30/24 6:00:00 AM ET
    $AKRO
    $APLS
    $AUPH
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKRO alert in real time by email

    -- Oversubscribed financing brings together leading syndicate of life sciences investors --

    -- Proceeds to support clinical development of first-in-class therapies for neurological disorders –

    BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain. Proceeds will also enable the development of next generation compounds targeting KCC2 in these and other indications, including psychiatric and neurodevelopmental disorders.

    Axonis Therapeutics

    Cormorant Asset Management and venBio Partners co-led the financing with significant investments from Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, Lumira Ventures and Solasta Ventures. In conjunction with this financing, Axonis named Raymond J. Kelleher, M.D., Ph.D., Managing Director at Cormorant Asset Management and Jonathan Leff, M.D., Executive Partner, Private Equity, from Sofinnova Investments to its Board of Directors. Eos Bioinnovation, Hatteras Venture Partners, SCI Ventures, Alexandria Venture Investments, Tachyon Ventures, BoxOne, Iaso Ventures and Pathway Bioventures also participated in the financing.

    "Axonis' vision is to advance a pipeline of oral KCC2 therapeutics to restore functional inhibition in the CNS to treat neurological disorders without disabling side effects," said Joanna Stanicka, Ph.D., Chief Executive Officer, President, and co-founder of Axonis. "As we head into the clinic later this year, this financing is a significant milestone for Axonis as we translate our exciting science into efficacious and well-tolerated treatments for patients suffering from neurological disorders."

    "We're delighted that this accomplished group of investors share our mission to translate Axonis' science into impactful medicines," said Corey Goodman, Ph.D., Executive Chair and co-founder of Axonis. "I'm pleased to see how far the science has progressed at Axonis; what the team has accomplished is remarkable. We are now well positioned to bring our lead therapeutic program through clinical proof of concept and expand into related arenas and build a leading biotechnology company."

    Despite the approval of several drugs for epilepsy and pain, many patients do not tolerate or respond to current first-line therapies due to impaired synaptic inhibition, which can contribute to drug resistance. Axonis' oral KCC2 potentiators are designed to restore functional inhibition and overcome drug resistance in patients.

    "I'm enthusiastic about the potential of Axonis' novel precision approach to re-shape how we treat patients with neurological disorders, particularly epilepsy and pain where modulation of synaptic inhibition has great therapeutic promise," said Raymond J. Kelleher, M.D., Ph.D., Managing Director at Cormorant. "Axonis' scientists have done amazing work. We're very excited about what this program could mean for patients and their families."

    Leadership Team

    Axonis is led by Joanna Stanicka, Ph.D., co-founder and co-inventor of Axonis' underlying IP. She is a Harvard-trained scientist, drug hunter, and entrepreneur, and a recipient of the Massachusetts Next Generation Award, a prize in leadership for woman-CEO in life sciences. Shane Hegarty, Ph.D., is the company's Chief Scientific Officer, co-founder, and IP co-inventor. He was previously a Research Fellow at Harvard Medical School and Boston Children's Hospital, faculty member in Neuroscience Department of University College Cork, and recipient of the Neuroscience Ireland Investigator Award.

    In conjunction with the financing, Axonis also announces the appointments of Donald Manning, M.D., Ph.D., as Chief Medical Officer and Jeff Imbaro, M.B.A., as Chief Operating Officer. Dr. Manning is a clinician-scientist with comprehensive experience in acute and chronic clinical practice, research and management. He brings to Axonis over 25 years of executive experience, having overseen the filings of seven INDs and five NDAs that have led to nine approved products. Mr. Imbaro brings over 20 years of company building expertise, having led Business Development and General and Administrative functions of several successful biotech and pharmaceutical companies. He was a member of the founding team of Semma Therapeutics, which was later acquired by Vertex Pharmaceuticals in 2019 for nearly $1 billion. 

    About Axonis Therapeutics

    Axonis Therapeutics is a neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children's Hospital, Harvard and Université Laval. The company has built a proprietary KCC2 discovery engine, based on several years of world-leading know-how, to become the leaders in this potential blockbuster drug space. Axonis is grateful for grant awards and support received from National Institutes of Health, Department of Defense SCIRP, ISS National Lab, CURE Epilepsy, Wings for Life, Massachusetts Life Center, SynGAP Research Fund, Praxis Spinal Cord Institute, Creative Destruction Lab, Springboard Enterprises and MassChallenge. The company is headquartered in Boston, MA. For more information, visit www.axonis.us.

    About venBio Partners

    Since inception in 2011, venBio has raised roughly $2 billion in capital commitments and led investment rounds in 40+ companies, including Labrys Biologics (acquired by Teva), Aragon Pharmaceuticals (acquired by Johnson & Johnson), Seragon Pharmaceuticals (acquired by Roche), Aurinia Pharmaceuticals (NASDAQ:AUPH), Apellis Pharmaceuticals (NASDAQ:APLS), Checkmate Pharmaceuticals (NASDAQ:CMPI, acquired by Regeneron)), Turning Point Therapeutics (NASDAQ:TPTX, acquired by BMS)), Akero Therapeutics (NASDAQ:AKRO), Harmony Biosciences (NASDAQ:HRMY), Pharvaris (NASDAQ:PHVS), CinCor Pharma (NASDAQ:CINC, acquired by Astra Zeneca)), RayzeBio (NASDAQ:RYZB, acquired by BMS)), and many others. For more information, visit the venBio website at www.venbio.com and follow on LinkedIn.

    About Cormorant Asset Management

    Founded in 2013, Cormorant Asset Management, LP ("Cormorant") is a leading life sciences-focused investment firm with over $3 billion of assets under management. Cormorant is driven by a deep focus on fundamental scientific principles and provides financial resources to support the most innovative and promising publicly traded and private companies in biotech and allied sectors. Cormorant is among the most active crossover investors in life sciences, with investments in over 100 privately held, life science-focused companies during the past decade. 

    Media Contact

    Argot Partners

    Sarah Sutton

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/axonis-therapeutics-announces-115-million-series-a-financing-302290888.html

    SOURCE Axonis Therapeutics

    Get the next $AKRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Q&A

    New
    • What was the amount raised by Axonis Therapeutics and what is it intended for?

      Axonis Therapeutics raised $115 million in an oversubscribed Series A financing to support the clinical development of their lead compound, AXN-027.

    • What is AXN-027 and what conditions is it targeting?

      AXN-027 is a first-in-class oral small molecule designed to enhance the function of KCC2, a CNS chloride transporter crucial for inhibitory neurotransmission, targeting conditions like epilepsy and pain.

    • Who led the financing round for Axonis Therapeutics?

      The lead investors in the financing were Cormorant Asset Management and venBio Partners, with participation from several other notable life sciences investors.

    • What will the proceeds from the financing support apart from AXN-027?

      The funds raised will also enable the development of next-generation compounds targeting KCC2 for various neurological and psychiatric disorders, beyond epilepsy and pain.

    • What is Axonis Therapeutics' vision for their drug development in the context of neurological disorders?

      Axonis aims to advance a pipeline of oral KCC2 therapeutics to restore functionality in inhibitory neurotransmission, ultimately improving treatments for neurological disorders without significant side effects.

    Recent Analyst Ratings for
    $AKRO
    $APLS
    $AUPH
    $HRMY

    CompanyDatePrice TargetRatingAnalyst
    Harmony Biosciences Holdings Inc.
    $HRMY
    7/21/2025$48.00Buy
    Truist
    Harmony Biosciences Holdings Inc.
    $HRMY
    7/10/2025$33.00Neutral
    Goldman
    Pharvaris N.V.
    $PHVS
    6/11/2025$32.00Buy
    Guggenheim
    Harmony Biosciences Holdings Inc.
    $HRMY
    6/2/2025$61.00Outperform
    Oppenheimer
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$52.00Strong Buy → Outperform
    Raymond James
    Pharvaris N.V.
    $PHVS
    4/29/2025$28.00Overweight
    Cantor Fitzgerald
    Apellis Pharmaceuticals Inc.
    $APLS
    4/29/2025$44.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Development Officer Yale Catriona exercised 10,000 shares at a strike of $19.87 and sold $529,467 worth of shares (10,000 units at $52.95) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      7/18/25 6:00:06 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Francois Cedric exercised 8,997 shares at a strike of $4.31 and sold $398,735 worth of shares (19,725 units at $20.21), decreasing direct ownership by 3% to 331,605 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      7/18/25 4:02:35 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Watson David O. sold $97,750 worth of shares (5,000 units at $19.55), decreasing direct ownership by 4% to 128,730 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      7/18/25 4:00:54 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    $APLS
    $AUPH
    $HRMY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

      Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

      5/17/21 11:09:40 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for LUPKYNIS

      Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity

      1/25/21 11:31:10 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

      ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the closing of its previously announced upsized underwritten public offering of 9,562,500 ordinary shares (which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,312,500 ordinary shares) and pre-funded warrants to purchase 500,000 ordinary shares. The gross proc

      7/24/25 4:05:58 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

      WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines c

      7/24/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

      ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shar

      7/22/25 9:22:41 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Harmony Biosciences with a new price target

      Truist initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $48.00

      7/21/25 8:34:40 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman resumed coverage on Harmony Biosciences with a new price target

      Goldman resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $33.00

      7/10/25 8:55:45 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Pharvaris N.V. with a new price target

      Guggenheim initiated coverage of Pharvaris N.V. with a rating of Buy and set a new price target of $32.00

      6/11/25 7:54:51 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      3/27/25 7:42:13 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Tang Kevin bought $12,713,126 worth of shares (1,600,000 units at $7.95) (SEC Form 4)

      4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

      3/4/25 5:03:02 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Graham G. Walmsley bought $9,600,000 worth of shares (200,000 units at $48.00) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      2/7/25 7:54:28 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    $APLS
    $AUPH
    $HRMY
    SEC Filings

    See more
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      7/24/25 4:18:38 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Pharvaris N.V.

      424B5 - Pharvaris N.V. (0001830487) (Filer)

      7/24/25 6:17:42 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form FWP filed by Pharvaris N.V.

      FWP - Pharvaris N.V. (0001830487) (Subject)

      7/22/25 9:03:20 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/22/24 4:16:13 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

      SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/22/24 8:47:59 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aurinia Pharmaceuticals Inc

      SC 13G/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

      11/14/24 4:47:34 PM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Leadership Updates

    Live Leadership Updates

    See more
    • NodThera Announces Appointment of Elisabeth Björk as Board Member

      NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

      6/17/25 7:00:00 AM ET
      $PHVS
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Announces Craig Wheeler to Join the Board of Directors

      WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. "We are thrilled to welcome Craig to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Craig is a seasoned leader, who has successfully grown biopharmaceutical companies into strong commercial organizations with robust pipelines

      4/21/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm

      4/3/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Financials

    Live finance-specific insights

    See more
    • Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

      WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines c

      7/24/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is

      7/22/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release second quarter 2025 financial and operational results before markets open on July 31, 2025. Aurinia's management team will host a conference call and webcast on July 31, 2025, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclos

      7/22/25 6:00:00 AM ET
      $AUPH
      Biotechnology: Pharmaceutical Preparations
      Health Care